Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
Open Access
- 18 May 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (1) , 230-238
Abstract
Background and Aims: There is an ongoing debate on whether NAFLD is an active contributor or an innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to assess the causal relationship between NAFLD and CAD. Approach and Results: We performed two‐sample Mendelian randomization (MR) analyses using summary‐level data to assess the association between genetically predicted NAFLD (i.e., chronically elevated serum alanine aminotransferase levels [cALT], imaging‐based and biopsy‐confirmed NAFLD) and risk of CAD. Analyses were repeated after exclusion of NAFLD susceptibility genes that are associated with impaired VLDL secretion. Inverse‐variance weighted MR analyses showed a statistically significant association between genetically predicted cALT and risk of CAD (OR: 1.116, 95% CI: 1.039, 1.199), but not for the other NAFLD‐related traits (OR: 1.046, 95% CI: 0.764, 1.433 and OR: 1.014, 95% CI: 0.968, 1.062 for imaging‐based and biopsy‐confirmed NAFLD, respectively). MR‐Egger regression revealed a statistically significant intercept, indicative of directional pleiotropy, for all traits. Repeat analyses after exclusion of genes associated with impaired VLDL secretion showed consistent associations between genetically predicted NAFLD and CAD for all traits (i.e., cALT [OR: 1.203, 95% CI: 1.113, 1.300]), imaging‐based (OR: 2.149, 95% CI: 1.276, 3.620) and biopsy‐confirmed NAFLD (OR: 1.113, 95% CI: 1.041, 1.189), which persisted when more stringent biopsy‐confirmed NAFLD criteria were used (OR: 1.154, 95% CI: 1.043, 1.278) or when more stringent MR methods were applied. MR‐Egger regression did not show a statistically significant intercept. Conclusion: The two‐sample MR analyses showed a robust association between genetically predicted NAFLD and CAD after exclusion of genetic variants that are implicated in impaired VLDL secretion.Keywords
This publication has 40 references indexed in Scilit:
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2014
- MTTP polymorphisms and susceptibility to non‐alcoholic fatty liver disease in a Han Chinese populationLiver International, 2013
- Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitroJournal of Hepatology, 2012
- Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variantsInternational Journal of Epidemiology, 2010
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 yearsGut, 2009
- Increased overall mortality and liver-related mortality in non-alcoholic fatty liver diseaseJournal of Hepatology, 2008
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?Human Genetics, 2007
- Overproduction of large VLDL particles is driven by increased liver fat content in manDiabetologia, 2006
- Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt ValuesHepatology, 2003